<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00979602</url>
  </required_header>
  <id_info>
    <org_study_id>113480</org_study_id>
    <nct_id>NCT00979602</nct_id>
  </id_info>
  <brief_title>Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older</brief_title>
  <official_title>A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety, immunogenicity, and relative
      efficacy of the H1N1 (swine) flu vaccines GSK2340273A and GSK2340274A in adults 18 years of
      age or older.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Collaborators: United States Department of Health and Human Services, Office of Biomedical
      Advanced Research and Development Authority
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 9, 2009</start_date>
  <completion_date type="Actual">February 1, 2011</completion_date>
  <primary_completion_date type="Actual">January 10, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Seroconverted (SCR) Subjects for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</measure>
    <time_frame>At Day 21</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject who had a post-vaccination titer higher than or equal to (≥)1:40 or at least a 4-fold increase of the pre-vaccination titer of ≥ 1:10. The Flu strain assessed was A/California/7/09 (H1N1)v-like (Flu A/CAL/7/09) in subjects of 18-60 years and older and 18-64 years and older, following the Committee for Medicinal Products for Human Use (CHMP) and the Center for Biologics Evaluation and Research (CBER) guidance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroprotected (SPR) Subjects for HI Antibodies Against the Flu A/CAL/7/09 H1N1 Virus Strain</measure>
    <time_frame>At Day 0</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) antibody titer ≥ 1:40 against the tested virus. The Flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroprotected (SPR) Subjects for HI Antibodies Against the Flu A/CAL/7/09 H1N1 Virus Strain</measure>
    <time_frame>At Day 21</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with serum HI antibody titer ≥ 1:40. The Flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</measure>
    <time_frame>At Day 21</time_frame>
    <description>SCF was defined as the fold increase in serum HI geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus, in subjects 18-60 years and older and 18-64 years and older, following the CHMP guidance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of A/California/7/2009 (H1N1)V-like Illness (ILI) Cases</measure>
    <time_frame>From Day 14 post-vaccination up to study end (at Day 385)</time_frame>
    <description>The analysis focused on Quantitative Reverse Transcription Polymerase Chain Reaction Assay (RT-qPCR)-confirmed A/California/7/2009 (H1N1)v-like illness (ILI) cases.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects for HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <description>Cut-off values assessed were greater than or equal to (≥) 1:10 in the sera of subjects seronegative before vaccination.
The Flu strains assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <description>Titers were presented as geometric mean titers (GMTs). The flu strain assessed was /California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects for HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</measure>
    <time_frame>At Day 42</time_frame>
    <description>Cut-off values assessed were greater than or equal to (≥) 1:10 in the sera of subjects seronegative before vaccination. The Flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</measure>
    <time_frame>At Day 42</time_frame>
    <description>Titers were presented as geometric mean titers (GMTs). The flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects for HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</measure>
    <time_frame>At Day 182</time_frame>
    <description>Cut-off values assessed were greater than or equal to ≥ 1:10 in the sera of subjects seronegative before vaccination. The Flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</measure>
    <time_frame>At Day 182</time_frame>
    <description>Titers were presented as geometric mean titers (GMTs). The flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted (SCR) Subjects for HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</measure>
    <time_frame>At Day 42</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject who had a post-vaccination titer ≥1:40 and at least a 4-fold increase of the pre-vaccination titer. The Flu strain assessed was A/California/7/09 (H1N1)v-like) (Flu A/CAL/7/09) in subjects of 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted (SCR) Subjects for HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</measure>
    <time_frame>At Day 182</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject who had a post-vaccination titer ≥1:40 and at least a 4-fold increase of the pre-vaccination titer. The Flu strain assessed was A/California/7/09 (H1N1)v-like) (Flu A/CAL/7/09) in subjects of 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected (SPR) Subjects for HI Antibodies Against the Flu A/CAL/7/09 H1N1 Virus Strain</measure>
    <time_frame>At Day 42</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with serum HI antibody titer ≥ 1:40. The Flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected (SPR) Subjects for HI Antibodies Against the Flu A/CAL/7/09 H1N1 Virus Strain</measure>
    <time_frame>At Day 182</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with serum HI antibody titer ≥ 1:40. The Flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</measure>
    <time_frame>At Day 42</time_frame>
    <description>SCF was defined as the fold increase in serum HI geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus, in subjects 18-60 years and older and 18-64 years and older, following the CHMP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factor (SCF) for HI Antibodies Against A/CAL/7/09 H1N1 Virus Strain</measure>
    <time_frame>At Day 182</time_frame>
    <description>SCF was defined as the fold increase in serum HI geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus, in subjects 18-60 years and older and 18-64 years and older, following the CHMP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of A/California Influenza Related Cases</measure>
    <time_frame>From Day 0 up to the end of ILI surveillance (Day 385)</time_frame>
    <description>Influenza related cases included: A/California/7/2009 (H1N1)v-like influenza illness (ILI) cases, pneumonia cases, RT-qPCR confirmed influenza, culture confirmed influenza and RT-qPCR confirmed influenza with pneumonia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ILI Symptoms in All Reported ILI Cases</measure>
    <time_frame>From Day 0 up to the end of ILI surveillance (Day 385)</time_frame>
    <description>Assessed ILI symptoms were fever [defined as oral temperature equal to or above (≥) 38.5 degrees Celsius (°C)], myalgia (muscle aches all over the body), cough, sore throat, runny/stuffy nose, short of breath, headache, vomiting, diarrhea, chills, fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ILI Symptoms in All Reported ILI Cases</measure>
    <time_frame>From Day 14 post-vaccination through the end of ILI surveillance (Day 385)</time_frame>
    <description>Assessed ILI symptoms were fever [defined as oral temperature equal to or above (≥) 38.5 degrees Celsius (°C)], myalgia (muscle aches all over the body), cough, sore throat, runny/stuffy nose, short of breath, headache, vomiting, diarrhea, chills, fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</measure>
    <time_frame>During the 7-day (Days 0-6) post-vaccination period</time_frame>
    <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Safety results were tabulated according to age stratification: adults aged 18-64 years and older (&gt;64y).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>During the 7-day (Days 0-6) post-vaccination period</time_frame>
    <description>Assessed solicited general symptoms were fatigue, fever [defined as axillary temperature equal to or above (≥) 38.0 degrees Celsius (°C)], headache, joint pain at other location, muscle aches, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. Safety results were tabulated according to age stratification: adults aged 18-64 years and older (&gt;64y).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Normal/Abnormal Biochemical and Haematological Levels</measure>
    <time_frame>At Days 7 and 21</time_frame>
    <description>Among biochemical and haematological parameters assessed were alanine aminotransferase [ALT], alkaline phosphatase [AP], aspartate aminotransferase [AST], basophils [BAS], total bilirubin [T/BIL], bilirubin direct [BIL/D], creatinine [CREA], eosinophils [EOS], hematocrit [HEM], haemoglobin [Hgb], lymphocytes [LYM], monocytes [MON], neutrophils [NEU], platelets [PLA], red blood cells [RBC], blood urea nitrogen [BUN] and white blood cells [WBC]. Levels of haematological/biochemical parameters assessed with respect to normal laboratory values were - unknown, below, within and above for subjects aged 18-64 years (18-64y) and &gt;64 years old (&gt;64y).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Medically-attended Adverse Events (MAEs)</measure>
    <time_frame>Throughout the entire study period (Day 0 - Day 385)</time_frame>
    <description>MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination. Safety results were tabulated according to age stratification: adults aged 18-64 years and older (&gt;64y).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)</measure>
    <time_frame>Throughout the entire study period (Day 0 - Day 385)</time_frame>
    <description>Potential immune-mediated diseases (pIMDs) represent a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Safety results were tabulated according to age stratification: adults aged 18-64 years and older (&gt;64y).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Within the 42-day (Days 0-41) post-vaccination period</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Safety results were tabulated according to age stratification: adults aged 18-64 years and older (&gt;64y).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>Throughout the entire study period (Day 0 - Day 385)</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Safety results were tabulated according to age stratification: adults aged 18-64 years and older (&gt;64y).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4048</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>GSK2340274A Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male or female subjects between and including 18 to 60 years of age and older (&gt;60 years) and between 18 to 64 years of age and older (&gt;64 years), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2340273A Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male or female subjects between and including 18 to 60 years of age and older (&gt;60 years) and between 18 to 64 years of age and older (&gt;64 years), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK2340274A</intervention_name>
    <description>One intramuscular injection</description>
    <arm_group_label>GSK2340274A Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK2340273A</intervention_name>
    <description>One intramuscular injection</description>
    <arm_group_label>GSK2340273A Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes can and will comply with the requirements of
             the protocol.

          -  Written informed consent obtained from the subject.

          -  Male and female adults, &gt;= 18 years of age at the time of the first vaccination.

          -  Satisfactory baseline medical assessment by history and physical examination.

          -  Safety laboratory test results within the parameters specified in the protocol.

          -  Comprehension of the study requirements, ability to comprehend and comply with
             procedures for collection of safety data, expressed availability for the required
             study period, and ability and willingness to attend scheduled visits as demonstrated
             by signature on the informed consent document.

          -  Access to a consistent means of telephone contact, which may be either in the home or
             at the workplace, land line, or mobile, but NOT a pay phone or other multiple-user
             device.

          -  Female subjects of non-childbearing potential may be enrolled in the study.

          -  Female subjects of childbearing potential may be enrolled in the study, if the
             subject:

          -  has practiced adequate contraception for 30 days prior to vaccination; and

          -  has a negative pregnancy test on the day of first vaccination; and

          -  has agreed to continue adequate contraception during the entire treatment period and
             for 2 months after completion of the vaccination series.

        Exclusion Criteria:

          -  Medical history of physician-confirmed infection with an A/California/7/2009
             (H1N1)v-like virus.

          -  Previous vaccination at any time with an A/California/7/2009 (H1N1)v-like virus
             vaccine.

          -  With the exception of seasonal influenza vaccination, administration of any vaccine(s)
             within 30 days before study vaccination on Day 0. Seasonal influenza vaccine may be
             administered up to 14 days prior to study vaccination on Day 0.

          -  Planned administration of any vaccine other than the study vaccines between Day 0 and
             the phlebotomy 21 days after vaccination.

          -  Planned administration of any monovalent pandemic (H1N1)v-like vaccine other than the
             study vaccines during the whole study (Day 0 - Day 385).

          -  Previous vaccination with an H1N1v-like virus vaccine or a medical history of
             physician-confirmed infection with an H1N1v-like virus.

          -  Presence of evidence of substance abuse or of neurological or psychiatric diagnoses
             which, although stable, are deemed by the investigator to render the potential subject
             unable/unlikely to provide accurate safety reports.

          -  Presence of a temperature &gt;= 38.0ºC (&gt;= 100.4 ºF), oral temperature assessment
             preferred, or acute symptoms greater than &quot;mild&quot; severity on the scheduled date of
             first vaccination.

          -  Diagnosed with cancer, or treatment for cancer, within 3 years.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  Receipt of systemic glucocorticoids within 1month prior to study enrollment, or any
             other cytotoxic or immunosuppressive drug within 6 months of study enrollment.
             Topical, intra-articularly injected, or inhaled glucocorticoids, topical calcineurin
             inhibitors, or imiquimod are allowed.

          -  Receipt of any immunoglobulins and/or any blood products within 3 months of study
             enrollment or planned administration of any of these products during the study period.

          -  Any significant disorder of coagulation or treatment with warfarin derivatives or
             heparin. Persons receiving individual doses of low molecular weight heparin are
             eligible if no such doses are given in the 24 hours before a study vaccination.
             Persons receiving prophylactic antiplatelet medications, e.g., low-dose
             acetylsalicylic acid, and without a clinically-apparent bleeding tendency, are
             eligible.

          -  History of an acute evolving neurological disorder or history of Guillain-Barré
             syndrome within 6 weeks of receipt of seasonal influenza vaccine.

          -  With the exception of seasonal influenza vaccination, administration of any vaccines
             within 30 days before study vaccination on Day 0. Seasonal influenza vaccine may be
             administered up to 14 days prior to study vaccination on Day 0.

          -  Planned administration of any vaccine other than the study vaccine between Day 0 and
             the phlebotomy 21 days after the second study vaccine dose.

          -  Use of any investigational or non-registered product within 30 days preceding the
             first dose of study vaccine, or planned use during the study period.

          -  Any known or suspected allergy to any constituent of influenza vaccines; a history of
             anaphylactic-type reaction to any constituent of influenza vaccines; or a history of
             severe adverse reaction to a previous influenza vaccine.

          -  Known pregnancy or a positive urine beta-human chorionic gonadotropin test result
             prior to vaccination.

          -  Lactating or nursing women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33484</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milford</city>
        <state>Massachusetts</state>
        <zip>01757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Camillus</city>
        <state>New York</state>
        <zip>13031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Willoughby Hills</city>
        <state>Ohio</state>
        <zip>44094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <zip>V3K 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bay Roberts</city>
        <state>Newfoundland and Labrador</state>
        <zip>A0A 1G0</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 3R5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6T 3T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5W 6A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 1H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3H 5S4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8Y 6S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1E 7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St-Romulad</city>
        <state>Quebec</state>
        <zip>G6W 5M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2009</study_first_submitted>
  <study_first_submitted_qc>September 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2009</study_first_posted>
  <results_first_submitted>August 25, 2017</results_first_submitted>
  <results_first_submitted_qc>August 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 21, 2017</results_first_posted>
  <disposition_first_submitted>February 4, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>February 4, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 9, 2011</disposition_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK Bio's influenza vaccine GSK2340274A</keyword>
  <keyword>Influenza Vaccines</keyword>
  <keyword>GSK Bio's influenza vaccine GSK2340273A</keyword>
  <keyword>influenza infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>113480</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113480</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113480</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113480</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113480</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113480</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113480</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GSK2340274A Group</title>
          <description>Healthy male or female subjects between and including 18 to 60 years of age and older (&gt;60 years) and between 18 to 64 years of age and older (&gt;64 years), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P2">
          <title>GSK2340273A Group</title>
          <description>Healthy male or female subjects between and including 18 to 60 years of age and older (&gt;60 years) and between 18 to 64 years of age and older (&gt;64 years), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2025"/>
                <participants group_id="P2" count="2023"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1880"/>
                <participants group_id="P2" count="1890"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="133"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Serious Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Migrated/moved from study area</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Others</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK2340274A Group</title>
          <description>Healthy male or female subjects between and including 18 to 60 years of age and older (&gt;60 years) and between 18 to 64 years of age and older (&gt;64 years), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B2">
          <title>GSK2340273A Group</title>
          <description>Healthy male or female subjects between and including 18 to 60 years of age and older (&gt;60 years) and between 18 to 64 years of age and older (&gt;64 years), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2025"/>
            <count group_id="B2" value="2023"/>
            <count group_id="B3" value="4048"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.5" spread="18.6"/>
                    <measurement group_id="B2" value="45.4" spread="18.3"/>
                    <measurement group_id="B3" value="45.5" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1185"/>
                    <measurement group_id="B2" value="1185"/>
                    <measurement group_id="B3" value="2370"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="840"/>
                    <measurement group_id="B2" value="838"/>
                    <measurement group_id="B3" value="1678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Geographic ancestry</title>
              <category_list>
                <category>
                  <title>African Heritage/African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="231"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaskan native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian - Central/South Asian Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian - East Asian Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian - Japanese Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian - South East Asian Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White - Arabic/North African Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White - Caucasian/European Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1787"/>
                    <measurement group_id="B2" value="1790"/>
                    <measurement group_id="B3" value="3577"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted (SCR) Subjects for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</title>
        <description>A seroconverted subject was defined as a vaccinated subject who had a post-vaccination titer higher than or equal to (≥)1:40 or at least a 4-fold increase of the pre-vaccination titer of ≥ 1:10. The Flu strain assessed was A/California/7/09 (H1N1)v-like (Flu A/CAL/7/09) in subjects of 18-60 years and older and 18-64 years and older, following the Committee for Medicinal Products for Human Use (CHMP) and the Center for Biologics Evaluation and Research (CBER) guidance.</description>
        <time_frame>At Day 21</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 21 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340274A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2340273A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>GSK2340274A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340274A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK2340273A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>GSK2340273A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted (SCR) Subjects for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</title>
          <description>A seroconverted subject was defined as a vaccinated subject who had a post-vaccination titer higher than or equal to (≥)1:40 or at least a 4-fold increase of the pre-vaccination titer of ≥ 1:10. The Flu strain assessed was A/California/7/09 (H1N1)v-like (Flu A/CAL/7/09) in subjects of 18-60 years and older and 18-64 years and older, following the Committee for Medicinal Products for Human Use (CHMP) and the Center for Biologics Evaluation and Research (CBER) guidance.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 21 were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1345"/>
                <count group_id="O2" value="535"/>
                <count group_id="O3" value="1338"/>
                <count group_id="O4" value="531"/>
                <count group_id="O5" value="1426"/>
                <count group_id="O6" value="454"/>
                <count group_id="O7" value="1414"/>
                <count group_id="O8" value="455"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1210"/>
                    <measurement group_id="O2" value="411"/>
                    <measurement group_id="O3" value="1012"/>
                    <measurement group_id="O4" value="301"/>
                    <measurement group_id="O5" value="1279"/>
                    <measurement group_id="O6" value="342"/>
                    <measurement group_id="O7" value="1055"/>
                    <measurement group_id="O8" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroprotected (SPR) Subjects for HI Antibodies Against the Flu A/CAL/7/09 H1N1 Virus Strain</title>
        <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) antibody titer ≥ 1:40 against the tested virus. The Flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity at Day 21, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 21 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340274A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2340273A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>GSK2340274A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340274A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK2340273A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>GSK2340273A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected (SPR) Subjects for HI Antibodies Against the Flu A/CAL/7/09 H1N1 Virus Strain</title>
          <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) antibody titer ≥ 1:40 against the tested virus. The Flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity at Day 21, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 21 were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1347"/>
                <count group_id="O2" value="535"/>
                <count group_id="O3" value="1344"/>
                <count group_id="O4" value="532"/>
                <count group_id="O5" value="1428"/>
                <count group_id="O6" value="454"/>
                <count group_id="O7" value="1420"/>
                <count group_id="O8" value="456"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="337"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="332"/>
                    <measurement group_id="O4" value="92"/>
                    <measurement group_id="O5" value="350"/>
                    <measurement group_id="O6" value="61"/>
                    <measurement group_id="O7" value="346"/>
                    <measurement group_id="O8" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroprotected (SPR) Subjects for HI Antibodies Against the Flu A/CAL/7/09 H1N1 Virus Strain</title>
        <description>A seroprotected subject was defined as a vaccinated subject with serum HI antibody titer ≥ 1:40. The Flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
        <time_frame>At Day 21</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity at Day 21, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 21 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340274A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2340273A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>GSK2340274A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340274A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK2340273A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>GSK2340273A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected (SPR) Subjects for HI Antibodies Against the Flu A/CAL/7/09 H1N1 Virus Strain</title>
          <description>A seroprotected subject was defined as a vaccinated subject with serum HI antibody titer ≥ 1:40. The Flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity at Day 21, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 21 were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1350"/>
                <count group_id="O2" value="539"/>
                <count group_id="O3" value="1347"/>
                <count group_id="O4" value="533"/>
                <count group_id="O5" value="1432"/>
                <count group_id="O6" value="457"/>
                <count group_id="O7" value="1424"/>
                <count group_id="O8" value="456"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1326"/>
                    <measurement group_id="O2" value="470"/>
                    <measurement group_id="O3" value="1246"/>
                    <measurement group_id="O4" value="371"/>
                    <measurement group_id="O5" value="1403"/>
                    <measurement group_id="O6" value="393"/>
                    <measurement group_id="O7" value="1302"/>
                    <measurement group_id="O8" value="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</title>
        <description>SCF was defined as the fold increase in serum HI geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus, in subjects 18-60 years and older and 18-64 years and older, following the CHMP guidance.</description>
        <time_frame>At Day 21</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity at Day 21, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 21 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340274A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2340273A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>GSK2340274A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340274A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK2340273A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>GSK2340273A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</title>
          <description>SCF was defined as the fold increase in serum HI geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus, in subjects 18-60 years and older and 18-64 years and older, following the CHMP guidance.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity at Day 21, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 21 were available.</population>
          <units>Fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1345"/>
                <count group_id="O2" value="535"/>
                <count group_id="O3" value="1338"/>
                <count group_id="O4" value="531"/>
                <count group_id="O5" value="1426"/>
                <count group_id="O6" value="454"/>
                <count group_id="O7" value="1414"/>
                <count group_id="O8" value="455"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" lower_limit="25.7" upper_limit="29.9"/>
                    <measurement group_id="O2" value="12.5" lower_limit="11.2" upper_limit="13.9"/>
                    <measurement group_id="O3" value="15.5" lower_limit="14.2" upper_limit="16.8"/>
                    <measurement group_id="O4" value="6.4" lower_limit="5.7" upper_limit="7.1"/>
                    <measurement group_id="O5" value="26.9" lower_limit="25.0" upper_limit="29.0"/>
                    <measurement group_id="O6" value="11.9" lower_limit="10.5" upper_limit="13.4"/>
                    <measurement group_id="O7" value="14.8" lower_limit="13.6" upper_limit="16.1"/>
                    <measurement group_id="O8" value="6.3" lower_limit="5.5" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of A/California/7/2009 (H1N1)V-like Illness (ILI) Cases</title>
        <description>The analysis focused on Quantitative Reverse Transcription Polymerase Chain Reaction Assay (RT-qPCR)-confirmed A/California/7/2009 (H1N1)v-like illness (ILI) cases.</description>
        <time_frame>From Day 14 post-vaccination up to study end (at Day 385)</time_frame>
        <population>The analysis was performed on the ATP cohort for efficacy, which included all eligible subjects who received the study vaccine according to their treatment assignment and who were successfully contacted at least once during the active influenza surveillance period after completing the Day 21 study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A Group</title>
            <description>Healthy male or female subjects between and including 18 to 60 years of age and older (&gt;60 years) and between 18 to 64 years of age and older (&gt;64 years), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340273A Group</title>
            <description>Healthy male or female subjects between and including 18 to 60 years of age and older (&gt;60 years) and between 18 to 64 years of age and older (&gt;64 years), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of A/California/7/2009 (H1N1)V-like Illness (ILI) Cases</title>
          <description>The analysis focused on Quantitative Reverse Transcription Polymerase Chain Reaction Assay (RT-qPCR)-confirmed A/California/7/2009 (H1N1)v-like illness (ILI) cases.</description>
          <population>The analysis was performed on the ATP cohort for efficacy, which included all eligible subjects who received the study vaccine according to their treatment assignment and who were successfully contacted at least once during the active influenza surveillance period after completing the Day 21 study visit.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1949"/>
                <count group_id="O2" value="1958"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects for HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</title>
        <description>Cut-off values assessed were greater than or equal to (≥) 1:10 in the sera of subjects seronegative before vaccination.
The Flu strains assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity at Day 21, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 21 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340274A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2340273A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>GSK2340274A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340274A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK2340273A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>GSK2340273A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seropositive Subjects for HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</title>
          <description>Cut-off values assessed were greater than or equal to (≥) 1:10 in the sera of subjects seronegative before vaccination.
The Flu strains assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity at Day 21, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 21 were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1350"/>
                <count group_id="O2" value="539"/>
                <count group_id="O3" value="1347"/>
                <count group_id="O4" value="533"/>
                <count group_id="O5" value="1432"/>
                <count group_id="O6" value="457"/>
                <count group_id="O7" value="1424"/>
                <count group_id="O8" value="456"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flu A/CAL/7/09, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1347"/>
                    <count group_id="O2" value="535"/>
                    <count group_id="O3" value="1344"/>
                    <count group_id="O4" value="532"/>
                    <count group_id="O5" value="1428"/>
                    <count group_id="O6" value="454"/>
                    <count group_id="O7" value="1420"/>
                    <count group_id="O8" value="456"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="754"/>
                    <measurement group_id="O2" value="293"/>
                    <measurement group_id="O3" value="731"/>
                    <measurement group_id="O4" value="312"/>
                    <measurement group_id="O5" value="803"/>
                    <measurement group_id="O6" value="244"/>
                    <measurement group_id="O7" value="775"/>
                    <measurement group_id="O8" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/CAL/7/09, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1350"/>
                    <count group_id="O2" value="539"/>
                    <count group_id="O3" value="1347"/>
                    <count group_id="O4" value="533"/>
                    <count group_id="O5" value="1432"/>
                    <count group_id="O6" value="457"/>
                    <count group_id="O7" value="1424"/>
                    <count group_id="O8" value="456"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1348"/>
                    <measurement group_id="O2" value="534"/>
                    <measurement group_id="O3" value="1335"/>
                    <measurement group_id="O4" value="512"/>
                    <measurement group_id="O5" value="1430"/>
                    <measurement group_id="O6" value="452"/>
                    <measurement group_id="O7" value="1410"/>
                    <measurement group_id="O8" value="437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</title>
        <description>Titers were presented as geometric mean titers (GMTs). The flu strain assessed was /California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity at Day 21, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 21 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340274A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2340273A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>GSK2340274A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340274A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK2340273A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>GSK2340273A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</title>
          <description>Titers were presented as geometric mean titers (GMTs). The flu strain assessed was /California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity at Day 21, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 21 were available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1350"/>
                <count group_id="O2" value="539"/>
                <count group_id="O3" value="1347"/>
                <count group_id="O4" value="533"/>
                <count group_id="O5" value="1432"/>
                <count group_id="O6" value="457"/>
                <count group_id="O7" value="1424"/>
                <count group_id="O8" value="456"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flu A/CAL/7/09, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1347"/>
                    <count group_id="O2" value="535"/>
                    <count group_id="O3" value="1344"/>
                    <count group_id="O4" value="532"/>
                    <count group_id="O5" value="1428"/>
                    <count group_id="O6" value="454"/>
                    <count group_id="O7" value="1420"/>
                    <count group_id="O8" value="456"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" lower_limit="13.9" upper_limit="16.0"/>
                    <measurement group_id="O2" value="11.0" lower_limit="10.1" upper_limit="11.9"/>
                    <measurement group_id="O3" value="14.8" lower_limit="13.8" upper_limit="15.8"/>
                    <measurement group_id="O4" value="12.2" lower_limit="11.2" upper_limit="13.3"/>
                    <measurement group_id="O5" value="14.7" lower_limit="13.8" upper_limit="15.7"/>
                    <measurement group_id="O6" value="10.9" lower_limit="10.0" upper_limit="11.9"/>
                    <measurement group_id="O7" value="14.7" lower_limit="13.7" upper_limit="15.7"/>
                    <measurement group_id="O8" value="12.0" lower_limit="11.0" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/CAL/7/09, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1350"/>
                    <count group_id="O2" value="539"/>
                    <count group_id="O3" value="1347"/>
                    <count group_id="O4" value="533"/>
                    <count group_id="O5" value="1432"/>
                    <count group_id="O6" value="457"/>
                    <count group_id="O7" value="1424"/>
                    <count group_id="O8" value="456"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="415.0" lower_limit="391.4" upper_limit="440.0"/>
                    <measurement group_id="O2" value="135.9" lower_limit="122.1" upper_limit="151.1"/>
                    <measurement group_id="O3" value="228.7" lower_limit="213.5" upper_limit="245.0"/>
                    <measurement group_id="O4" value="77.3" lower_limit="68.4" upper_limit="87.4"/>
                    <measurement group_id="O5" value="396.2" lower_limit="373.8" upper_limit="419.9"/>
                    <measurement group_id="O6" value="128.6" lower_limit="114.6" upper_limit="144.3"/>
                    <measurement group_id="O7" value="217.6" lower_limit="203.3" upper_limit="232.9"/>
                    <measurement group_id="O8" value="75.2" lower_limit="65.9" upper_limit="85.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects for HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</title>
        <description>Cut-off values assessed were greater than or equal to (≥) 1:10 in the sera of subjects seronegative before vaccination. The Flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
        <time_frame>At Day 42</time_frame>
        <population>The analysis was performed on a subset from the ATP cohort for immunogenicity at Day 42, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 42 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340274A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2340273A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>GSK2340274A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340274A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK2340273A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>GSK2340273A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seropositive Subjects for HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</title>
          <description>Cut-off values assessed were greater than or equal to (≥) 1:10 in the sera of subjects seronegative before vaccination. The Flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
          <population>The analysis was performed on a subset from the ATP cohort for immunogenicity at Day 42, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 42 were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="52"/>
                    <measurement group_id="O6" value="48"/>
                    <measurement group_id="O7" value="46"/>
                    <measurement group_id="O8" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</title>
        <description>Titers were presented as geometric mean titers (GMTs). The flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
        <time_frame>At Day 42</time_frame>
        <population>The analysis was performed on a subset from the ATP cohort for immunogenicity at Day 42, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 42 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340274A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2340273A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>GSK2340274A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340274A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK2340273A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>GSK2340273A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</title>
          <description>Titers were presented as geometric mean titers (GMTs). The flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
          <population>The analysis was performed on a subset from the ATP cohort for immunogenicity at Day 42, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 42 were available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288.5" lower_limit="215.9" upper_limit="385.5"/>
                    <measurement group_id="O2" value="105.4" lower_limit="70.8" upper_limit="157.0"/>
                    <measurement group_id="O3" value="177.2" lower_limit="121.3" upper_limit="259.0"/>
                    <measurement group_id="O4" value="47.9" lower_limit="33.1" upper_limit="69.2"/>
                    <measurement group_id="O5" value="276.5" lower_limit="207.1" upper_limit="369.0"/>
                    <measurement group_id="O6" value="105.9" lower_limit="70.2" upper_limit="159.9"/>
                    <measurement group_id="O7" value="170.0" lower_limit="117.7" upper_limit="245.4"/>
                    <measurement group_id="O8" value="47.2" lower_limit="32.1" upper_limit="69.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects for HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</title>
        <description>Cut-off values assessed were greater than or equal to ≥ 1:10 in the sera of subjects seronegative before vaccination. The Flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
        <time_frame>At Day 182</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity at Day 182, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 182 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340274A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2340273A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>GSK2340274A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340274A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK2340273A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>GSK2340273A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seropositive Subjects for HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</title>
          <description>Cut-off values assessed were greater than or equal to ≥ 1:10 in the sera of subjects seronegative before vaccination. The Flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity at Day 182, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 182 were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1306"/>
                <count group_id="O2" value="543"/>
                <count group_id="O3" value="1314"/>
                <count group_id="O4" value="536"/>
                <count group_id="O5" value="1388"/>
                <count group_id="O6" value="461"/>
                <count group_id="O7" value="1391"/>
                <count group_id="O8" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1282"/>
                    <measurement group_id="O2" value="501"/>
                    <measurement group_id="O3" value="1257"/>
                    <measurement group_id="O4" value="449"/>
                    <measurement group_id="O5" value="1361"/>
                    <measurement group_id="O6" value="422"/>
                    <measurement group_id="O7" value="1324"/>
                    <measurement group_id="O8" value="382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</title>
        <description>Titers were presented as geometric mean titers (GMTs). The flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
        <time_frame>At Day 182</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity at Day 182, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 182 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340274A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2340273A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>GSK2340274A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340274A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK2340273A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>GSK2340273A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</title>
          <description>Titers were presented as geometric mean titers (GMTs). The flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity at Day 182, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 182 were available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1306"/>
                <count group_id="O2" value="543"/>
                <count group_id="O3" value="1314"/>
                <count group_id="O4" value="536"/>
                <count group_id="O5" value="1388"/>
                <count group_id="O6" value="461"/>
                <count group_id="O7" value="1391"/>
                <count group_id="O8" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.5" lower_limit="107.8" upper_limit="123.7"/>
                    <measurement group_id="O2" value="38.4" lower_limit="34.6" upper_limit="42.6"/>
                    <measurement group_id="O3" value="87.6" lower_limit="81.4" upper_limit="94.3"/>
                    <measurement group_id="O4" value="30.1" lower_limit="26.9" upper_limit="33.6"/>
                    <measurement group_id="O5" value="109.5" lower_limit="102.3" upper_limit="117.1"/>
                    <measurement group_id="O6" value="37.1" lower_limit="33.2" upper_limit="41.5"/>
                    <measurement group_id="O7" value="83.3" lower_limit="77.5" upper_limit="89.5"/>
                    <measurement group_id="O8" value="29.2" lower_limit="26.0" upper_limit="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted (SCR) Subjects for HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</title>
        <description>A seroconverted subject was defined as a vaccinated subject who had a post-vaccination titer ≥1:40 and at least a 4-fold increase of the pre-vaccination titer. The Flu strain assessed was A/California/7/09 (H1N1)v-like) (Flu A/CAL/7/09) in subjects of 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
        <time_frame>At Day 42</time_frame>
        <population>The analysis was performed on a subset from the ATP cohort for immunogenicity at Day 42, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 42 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340274A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2340273A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>GSK2340274A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340274A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK2340273A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>GSK2340273A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted (SCR) Subjects for HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</title>
          <description>A seroconverted subject was defined as a vaccinated subject who had a post-vaccination titer ≥1:40 and at least a 4-fold increase of the pre-vaccination titer. The Flu strain assessed was A/California/7/09 (H1N1)v-like) (Flu A/CAL/7/09) in subjects of 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
          <population>The analysis was performed on a subset from the ATP cohort for immunogenicity at Day 42, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 42 were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="51"/>
                    <measurement group_id="O6" value="34"/>
                    <measurement group_id="O7" value="36"/>
                    <measurement group_id="O8" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted (SCR) Subjects for HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</title>
        <description>A seroconverted subject was defined as a vaccinated subject who had a post-vaccination titer ≥1:40 and at least a 4-fold increase of the pre-vaccination titer. The Flu strain assessed was A/California/7/09 (H1N1)v-like) (Flu A/CAL/7/09) in subjects of 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
        <time_frame>At Day 182</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity at Day 182, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 182 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340274A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2340273A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>GSK2340274A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340274A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK2340273A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>GSK2340273A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted (SCR) Subjects for HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</title>
          <description>A seroconverted subject was defined as a vaccinated subject who had a post-vaccination titer ≥1:40 and at least a 4-fold increase of the pre-vaccination titer. The Flu strain assessed was A/California/7/09 (H1N1)v-like) (Flu A/CAL/7/09) in subjects of 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity at Day 182, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 182 were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1302"/>
                <count group_id="O2" value="539"/>
                <count group_id="O3" value="1304"/>
                <count group_id="O4" value="534"/>
                <count group_id="O5" value="1383"/>
                <count group_id="O6" value="458"/>
                <count group_id="O7" value="1380"/>
                <count group_id="O8" value="458"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="823"/>
                    <measurement group_id="O2" value="198"/>
                    <measurement group_id="O3" value="717"/>
                    <measurement group_id="O4" value="146"/>
                    <measurement group_id="O5" value="861"/>
                    <measurement group_id="O6" value="160"/>
                    <measurement group_id="O7" value="741"/>
                    <measurement group_id="O8" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected (SPR) Subjects for HI Antibodies Against the Flu A/CAL/7/09 H1N1 Virus Strain</title>
        <description>A seroprotected subject was defined as a vaccinated subject with serum HI antibody titer ≥ 1:40. The Flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
        <time_frame>At Day 42</time_frame>
        <population>The analysis was performed on a subset from the ATP cohort for immunogenicity at Day 42, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 42 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340274A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2340273A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>GSK2340274A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340274A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK2340273A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>GSK2340273A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected (SPR) Subjects for HI Antibodies Against the Flu A/CAL/7/09 H1N1 Virus Strain</title>
          <description>A seroprotected subject was defined as a vaccinated subject with serum HI antibody titer ≥ 1:40. The Flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
          <population>The analysis was performed on a subset from the ATP cohort for immunogenicity at Day 42, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 42 were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="51"/>
                    <measurement group_id="O6" value="36"/>
                    <measurement group_id="O7" value="43"/>
                    <measurement group_id="O8" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected (SPR) Subjects for HI Antibodies Against the Flu A/CAL/7/09 H1N1 Virus Strain</title>
        <description>A seroprotected subject was defined as a vaccinated subject with serum HI antibody titer ≥ 1:40. The Flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
        <time_frame>At Day 182</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity at Day 182, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 182 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340274A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2340273A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>GSK2340274A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340274A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK2340273A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>GSK2340273A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected (SPR) Subjects for HI Antibodies Against the Flu A/CAL/7/09 H1N1 Virus Strain</title>
          <description>A seroprotected subject was defined as a vaccinated subject with serum HI antibody titer ≥ 1:40. The Flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) in subjects 18-60 years and older and 18-64 years and older, following the CHMP and the CBER guidance.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity at Day 182, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 182 were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1306"/>
                <count group_id="O2" value="543"/>
                <count group_id="O3" value="1314"/>
                <count group_id="O4" value="536"/>
                <count group_id="O5" value="1388"/>
                <count group_id="O6" value="461"/>
                <count group_id="O7" value="1391"/>
                <count group_id="O8" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1091"/>
                    <measurement group_id="O2" value="286"/>
                    <measurement group_id="O3" value="1009"/>
                    <measurement group_id="O4" value="236"/>
                    <measurement group_id="O5" value="1140"/>
                    <measurement group_id="O6" value="237"/>
                    <measurement group_id="O7" value="1047"/>
                    <measurement group_id="O8" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</title>
        <description>SCF was defined as the fold increase in serum HI geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus, in subjects 18-60 years and older and 18-64 years and older, following the CHMP.</description>
        <time_frame>At Day 42</time_frame>
        <population>The analysis was performed on a subset from the ATP cohort for immunogenicity at Day 42, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 42 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340274A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2340273A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>GSK2340274A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340274A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK2340273A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>GSK2340273A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain</title>
          <description>SCF was defined as the fold increase in serum HI geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus, in subjects 18-60 years and older and 18-64 years and older, following the CHMP.</description>
          <population>The analysis was performed on a subset from the ATP cohort for immunogenicity at Day 42, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 42 were available.</population>
          <units>Fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8" lower_limit="20.0" upper_limit="35.8"/>
                    <measurement group_id="O2" value="11.1" lower_limit="7.7" upper_limit="16.0"/>
                    <measurement group_id="O3" value="13.7" lower_limit="9.1" upper_limit="20.6"/>
                    <measurement group_id="O4" value="4.0" lower_limit="2.9" upper_limit="5.5"/>
                    <measurement group_id="O5" value="26.1" lower_limit="19.7" upper_limit="34.6"/>
                    <measurement group_id="O6" value="11.0" lower_limit="7.5" upper_limit="16.1"/>
                    <measurement group_id="O7" value="13.2" lower_limit="8.8" upper_limit="19.7"/>
                    <measurement group_id="O8" value="3.9" lower_limit="2.9" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factor (SCF) for HI Antibodies Against A/CAL/7/09 H1N1 Virus Strain</title>
        <description>SCF was defined as the fold increase in serum HI geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus, in subjects 18-60 years and older and 18-64 years and older, following the CHMP.</description>
        <time_frame>At Day 182</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity at Day 182, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 182 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340274A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A (18-60 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 60 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2340273A (&gt;60 y) Group</title>
            <description>Healthy male or female subjects older than 60 years of age (&gt;60 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>GSK2340274A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>GSK2340274A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK2340273A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O8">
            <title>GSK2340273A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor (SCF) for HI Antibodies Against A/CAL/7/09 H1N1 Virus Strain</title>
          <description>SCF was defined as the fold increase in serum HI geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus, in subjects 18-60 years and older and 18-64 years and older, following the CHMP.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity at Day 182, which included all evaluable subjects who received the study vaccine according to their treatment assignment and for whom the assay results for antibodies against A/California-like HA antigen for the blood sample taken on Day 182 were available.</population>
          <units>Fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1302"/>
                <count group_id="O2" value="539"/>
                <count group_id="O3" value="1304"/>
                <count group_id="O4" value="534"/>
                <count group_id="O5" value="1383"/>
                <count group_id="O6" value="458"/>
                <count group_id="O7" value="1380"/>
                <count group_id="O8" value="458"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="7.2" upper_limit="8.4"/>
                    <measurement group_id="O2" value="3.5" lower_limit="3.2" upper_limit="3.9"/>
                    <measurement group_id="O3" value="5.9" lower_limit="5.4" upper_limit="6.4"/>
                    <measurement group_id="O4" value="2.5" lower_limit="2.3" upper_limit="2.8"/>
                    <measurement group_id="O5" value="7.5" lower_limit="6.9" upper_limit="8.1"/>
                    <measurement group_id="O6" value="3.4" lower_limit="3.0" upper_limit="3.8"/>
                    <measurement group_id="O7" value="5.6" lower_limit="5.2" upper_limit="6.1"/>
                    <measurement group_id="O8" value="2.5" lower_limit="2.2" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of A/California Influenza Related Cases</title>
        <description>Influenza related cases included: A/California/7/2009 (H1N1)v-like influenza illness (ILI) cases, pneumonia cases, RT-qPCR confirmed influenza, culture confirmed influenza and RT-qPCR confirmed influenza with pneumonia.</description>
        <time_frame>From Day 0 up to the end of ILI surveillance (Day 385)</time_frame>
        <population>The analysis was performed on the ATP cohort for efficacy, which included all eligible subjects who received the study vaccine according to their treatment assignment and who were successfully contacted at least once during the active influenza surveillance period after completing the Day 21 study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A Group</title>
            <description>Healthy male or female subjects between and including 18 to 60 years of age and older (&gt;60 years) and between 18 to 64 years of age and older (&gt;64 years), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340273A Group</title>
            <description>Healthy male or female subjects between and including 18 to 60 years of age and older (&gt;60 years) and between 18 to 64 years of age and older (&gt;64 years), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of A/California Influenza Related Cases</title>
          <description>Influenza related cases included: A/California/7/2009 (H1N1)v-like influenza illness (ILI) cases, pneumonia cases, RT-qPCR confirmed influenza, culture confirmed influenza and RT-qPCR confirmed influenza with pneumonia.</description>
          <population>The analysis was performed on the ATP cohort for efficacy, which included all eligible subjects who received the study vaccine according to their treatment assignment and who were successfully contacted at least once during the active influenza surveillance period after completing the Day 21 study visit.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1949"/>
                <count group_id="O2" value="1958"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ILI cases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195"/>
                    <measurement group_id="O2" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia cases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RT-qPCR confirmed influenza</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Culture confirmed influenza</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RT-qPCR confirmed influenza with pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of ILI Symptoms in All Reported ILI Cases</title>
        <description>Assessed ILI symptoms were fever [defined as oral temperature equal to or above (≥) 38.5 degrees Celsius (°C)], myalgia (muscle aches all over the body), cough, sore throat, runny/stuffy nose, short of breath, headache, vomiting, diarrhea, chills, fatigue.</description>
        <time_frame>From Day 0 up to the end of ILI surveillance (Day 385)</time_frame>
        <population>The analysis was performed on the ATP cohort for efficacy, which included all eligible subjects who received the study vaccine according to their treatment assignment and who were successfully contacted at least once during the active influenza surveillance period after completing the Day 21 study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A Group</title>
            <description>Healthy male or female subjects between and including 18 to 60 years of age and older (&gt;60 years) and between 18 to 64 years of age and older (&gt;64 years), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340273A Group</title>
            <description>Healthy male or female subjects between and including 18 to 60 years of age and older (&gt;60 years) and between 18 to 64 years of age and older (&gt;64 years), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of ILI Symptoms in All Reported ILI Cases</title>
          <description>Assessed ILI symptoms were fever [defined as oral temperature equal to or above (≥) 38.5 degrees Celsius (°C)], myalgia (muscle aches all over the body), cough, sore throat, runny/stuffy nose, short of breath, headache, vomiting, diarrhea, chills, fatigue.</description>
          <population>The analysis was performed on the ATP cohort for efficacy, which included all eligible subjects who received the study vaccine according to their treatment assignment and who were successfully contacted at least once during the active influenza surveillance period after completing the Day 21 study visit.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1949"/>
                <count group_id="O2" value="1958"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore throat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny or stuffy nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Short of breath</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of ILI Symptoms in All Reported ILI Cases</title>
        <description>Assessed ILI symptoms were fever [defined as oral temperature equal to or above (≥) 38.5 degrees Celsius (°C)], myalgia (muscle aches all over the body), cough, sore throat, runny/stuffy nose, short of breath, headache, vomiting, diarrhea, chills, fatigue.</description>
        <time_frame>From Day 14 post-vaccination through the end of ILI surveillance (Day 385)</time_frame>
        <population>The analysis was performed on the ATP cohort for efficacy, which included all eligible subjects who received the study vaccine according to their treatment assignment and who were successfully contacted at least once during the active influenza surveillance period after completing the Day 21 study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A Group</title>
            <description>Healthy male or female subjects between and including 18 to 60 years of age and older (&gt;60 years) and between 18 to 64 years of age and older (&gt;64 years), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340273A Group</title>
            <description>Healthy male or female subjects between and including 18 to 60 years of age and older (&gt;60 years) and between 18 to 64 years of age and older (&gt;64 years), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of ILI Symptoms in All Reported ILI Cases</title>
          <description>Assessed ILI symptoms were fever [defined as oral temperature equal to or above (≥) 38.5 degrees Celsius (°C)], myalgia (muscle aches all over the body), cough, sore throat, runny/stuffy nose, short of breath, headache, vomiting, diarrhea, chills, fatigue.</description>
          <population>The analysis was performed on the ATP cohort for efficacy, which included all eligible subjects who received the study vaccine according to their treatment assignment and who were successfully contacted at least once during the active influenza surveillance period after completing the Day 21 study visit.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1949"/>
                <count group_id="O2" value="1958"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore throat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny or stuffy nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Short of breath</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</title>
        <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Safety results were tabulated according to age stratification: adults aged 18-64 years and older (&gt;64y).</description>
        <time_frame>During the 7-day (Days 0-6) post-vaccination period</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects who filled in their symptom sheets.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340274A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2340273A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</title>
          <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Safety results were tabulated according to age stratification: adults aged 18-64 years and older (&gt;64y).</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects who filled in their symptom sheets.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1529"/>
                <count group_id="O2" value="480"/>
                <count group_id="O3" value="1531"/>
                <count group_id="O4" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1256"/>
                    <measurement group_id="O2" value="272"/>
                    <measurement group_id="O3" value="458"/>
                    <measurement group_id="O4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
        <description>Assessed solicited general symptoms were fatigue, fever [defined as axillary temperature equal to or above (≥) 38.0 degrees Celsius (°C)], headache, joint pain at other location, muscle aches, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. Safety results were tabulated according to age stratification: adults aged 18-64 years and older (&gt;64y).</description>
        <time_frame>During the 7-day (Days 0-6) post-vaccination period</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects who filled in their symptom sheets.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340274A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2340273A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
          <description>Assessed solicited general symptoms were fatigue, fever [defined as axillary temperature equal to or above (≥) 38.0 degrees Celsius (°C)], headache, joint pain at other location, muscle aches, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. Safety results were tabulated according to age stratification: adults aged 18-64 years and older (&gt;64y).</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects who filled in their symptom sheets.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1529"/>
                <count group_id="O2" value="480"/>
                <count group_id="O3" value="1531"/>
                <count group_id="O4" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="473"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="361"/>
                    <measurement group_id="O4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="382"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="298"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="452"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="421"/>
                    <measurement group_id="O4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="359"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="312"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Joint pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="135"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Joint pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Joint pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="112"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Muscle aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="600"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="281"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Muscle aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Muscle aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="531"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="240"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="76"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="76"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Normal/Abnormal Biochemical and Haematological Levels</title>
        <description>Among biochemical and haematological parameters assessed were alanine aminotransferase [ALT], alkaline phosphatase [AP], aspartate aminotransferase [AST], basophils [BAS], total bilirubin [T/BIL], bilirubin direct [BIL/D], creatinine [CREA], eosinophils [EOS], hematocrit [HEM], haemoglobin [Hgb], lymphocytes [LYM], monocytes [MON], neutrophils [NEU], platelets [PLA], red blood cells [RBC], blood urea nitrogen [BUN] and white blood cells [WBC]. Levels of haematological/biochemical parameters assessed with respect to normal laboratory values were – unknown, below, within and above for subjects aged 18-64 years (18-64y) and &gt;64 years old (&gt;64y).</description>
        <time_frame>At Days 7 and 21</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340274A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2340273A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Normal/Abnormal Biochemical and Haematological Levels</title>
          <description>Among biochemical and haematological parameters assessed were alanine aminotransferase [ALT], alkaline phosphatase [AP], aspartate aminotransferase [AST], basophils [BAS], total bilirubin [T/BIL], bilirubin direct [BIL/D], creatinine [CREA], eosinophils [EOS], hematocrit [HEM], haemoglobin [Hgb], lymphocytes [LYM], monocytes [MON], neutrophils [NEU], platelets [PLA], red blood cells [RBC], blood urea nitrogen [BUN] and white blood cells [WBC]. Levels of haematological/biochemical parameters assessed with respect to normal laboratory values were – unknown, below, within and above for subjects aged 18-64 years (18-64y) and &gt;64 years old (&gt;64y).</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1527"/>
                <count group_id="O2" value="479"/>
                <count group_id="O3" value="1524"/>
                <count group_id="O4" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT, Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1527"/>
                    <count group_id="O2" value="479"/>
                    <count group_id="O3" value="1524"/>
                    <count group_id="O4" value="478"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1497"/>
                    <measurement group_id="O2" value="471"/>
                    <measurement group_id="O3" value="1482"/>
                    <measurement group_id="O4" value="472"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1493"/>
                    <count group_id="O2" value="473"/>
                    <count group_id="O3" value="1492"/>
                    <count group_id="O4" value="474"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1455"/>
                    <measurement group_id="O2" value="469"/>
                    <measurement group_id="O3" value="1437"/>
                    <measurement group_id="O4" value="469"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP, Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1527"/>
                    <count group_id="O2" value="479"/>
                    <count group_id="O3" value="1523"/>
                    <count group_id="O4" value="478"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1497"/>
                    <measurement group_id="O2" value="463"/>
                    <measurement group_id="O3" value="1495"/>
                    <measurement group_id="O4" value="468"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1493"/>
                    <count group_id="O2" value="473"/>
                    <count group_id="O3" value="1492"/>
                    <count group_id="O4" value="474"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1461"/>
                    <measurement group_id="O2" value="463"/>
                    <measurement group_id="O3" value="1469"/>
                    <measurement group_id="O4" value="464"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1527"/>
                    <count group_id="O2" value="479"/>
                    <count group_id="O3" value="1524"/>
                    <count group_id="O4" value="478"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1505"/>
                    <measurement group_id="O2" value="475"/>
                    <measurement group_id="O3" value="1493"/>
                    <measurement group_id="O4" value="473"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1493"/>
                    <count group_id="O2" value="473"/>
                    <count group_id="O3" value="1492"/>
                    <count group_id="O4" value="474"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1466"/>
                    <measurement group_id="O2" value="472"/>
                    <measurement group_id="O3" value="1459"/>
                    <measurement group_id="O4" value="468"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS, Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1526"/>
                    <count group_id="O2" value="479"/>
                    <count group_id="O3" value="1523"/>
                    <count group_id="O4" value="478"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1511"/>
                    <measurement group_id="O2" value="471"/>
                    <measurement group_id="O3" value="1515"/>
                    <measurement group_id="O4" value="477"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1493"/>
                    <count group_id="O2" value="473"/>
                    <count group_id="O3" value="1492"/>
                    <count group_id="O4" value="474"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1458"/>
                    <measurement group_id="O2" value="463"/>
                    <measurement group_id="O3" value="1460"/>
                    <measurement group_id="O4" value="466"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T/BIL, Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1527"/>
                    <count group_id="O2" value="479"/>
                    <count group_id="O3" value="1524"/>
                    <count group_id="O4" value="478"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1511"/>
                    <measurement group_id="O2" value="475"/>
                    <measurement group_id="O3" value="1500"/>
                    <measurement group_id="O4" value="472"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T/BIL, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1493"/>
                    <count group_id="O2" value="473"/>
                    <count group_id="O3" value="1492"/>
                    <count group_id="O4" value="474"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1467"/>
                    <measurement group_id="O2" value="468"/>
                    <measurement group_id="O3" value="1466"/>
                    <measurement group_id="O4" value="467"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL/D, Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1527"/>
                    <count group_id="O2" value="479"/>
                    <count group_id="O3" value="1524"/>
                    <count group_id="O4" value="478"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1524"/>
                    <measurement group_id="O2" value="478"/>
                    <measurement group_id="O3" value="1518"/>
                    <measurement group_id="O4" value="475"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL/D, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1493"/>
                    <count group_id="O2" value="473"/>
                    <count group_id="O3" value="1492"/>
                    <count group_id="O4" value="474"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1484"/>
                    <measurement group_id="O2" value="473"/>
                    <measurement group_id="O3" value="1488"/>
                    <measurement group_id="O4" value="473"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA, Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1527"/>
                    <count group_id="O2" value="479"/>
                    <count group_id="O3" value="1523"/>
                    <count group_id="O4" value="478"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="144"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1365"/>
                    <measurement group_id="O2" value="443"/>
                    <measurement group_id="O3" value="1363"/>
                    <measurement group_id="O4" value="443"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1493"/>
                    <count group_id="O2" value="473"/>
                    <count group_id="O3" value="1492"/>
                    <count group_id="O4" value="474"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="136"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1324"/>
                    <measurement group_id="O2" value="431"/>
                    <measurement group_id="O3" value="1345"/>
                    <measurement group_id="O4" value="438"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS, Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1526"/>
                    <count group_id="O2" value="479"/>
                    <count group_id="O3" value="1523"/>
                    <count group_id="O4" value="478"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1411"/>
                    <measurement group_id="O2" value="437"/>
                    <measurement group_id="O3" value="1414"/>
                    <measurement group_id="O4" value="449"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1493"/>
                    <count group_id="O2" value="473"/>
                    <count group_id="O3" value="1492"/>
                    <count group_id="O4" value="474"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1345"/>
                    <measurement group_id="O2" value="427"/>
                    <measurement group_id="O3" value="1361"/>
                    <measurement group_id="O4" value="437"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HEM, Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1526"/>
                    <count group_id="O2" value="479"/>
                    <count group_id="O3" value="1523"/>
                    <count group_id="O4" value="478"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="82"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1429"/>
                    <measurement group_id="O2" value="463"/>
                    <measurement group_id="O3" value="1416"/>
                    <measurement group_id="O4" value="467"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HEM, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1493"/>
                    <count group_id="O2" value="473"/>
                    <count group_id="O3" value="1492"/>
                    <count group_id="O4" value="474"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="91"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1368"/>
                    <measurement group_id="O2" value="451"/>
                    <measurement group_id="O3" value="1362"/>
                    <measurement group_id="O4" value="453"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HgB, Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1526"/>
                    <count group_id="O2" value="479"/>
                    <count group_id="O3" value="1523"/>
                    <count group_id="O4" value="478"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1455"/>
                    <measurement group_id="O2" value="465"/>
                    <measurement group_id="O3" value="1436"/>
                    <measurement group_id="O4" value="470"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HgB, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1493"/>
                    <count group_id="O2" value="473"/>
                    <count group_id="O3" value="1492"/>
                    <count group_id="O4" value="474"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1399"/>
                    <measurement group_id="O2" value="460"/>
                    <measurement group_id="O3" value="1385"/>
                    <measurement group_id="O4" value="456"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM, Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1526"/>
                    <count group_id="O2" value="479"/>
                    <count group_id="O3" value="1523"/>
                    <count group_id="O4" value="478"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1494"/>
                    <measurement group_id="O2" value="466"/>
                    <measurement group_id="O3" value="1500"/>
                    <measurement group_id="O4" value="468"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1493"/>
                    <count group_id="O2" value="473"/>
                    <count group_id="O3" value="1492"/>
                    <count group_id="O4" value="474"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1445"/>
                    <measurement group_id="O2" value="454"/>
                    <measurement group_id="O3" value="1444"/>
                    <measurement group_id="O4" value="452"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON, Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1526"/>
                    <count group_id="O2" value="479"/>
                    <count group_id="O3" value="1523"/>
                    <count group_id="O4" value="478"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="306"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="290"/>
                    <measurement group_id="O4" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1205"/>
                    <measurement group_id="O2" value="417"/>
                    <measurement group_id="O3" value="1224"/>
                    <measurement group_id="O4" value="423"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1493"/>
                    <count group_id="O2" value="473"/>
                    <count group_id="O3" value="1492"/>
                    <count group_id="O4" value="474"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="309"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="304"/>
                    <measurement group_id="O4" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1149"/>
                    <measurement group_id="O2" value="404"/>
                    <measurement group_id="O3" value="1155"/>
                    <measurement group_id="O4" value="402"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU, Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1522"/>
                    <count group_id="O2" value="477"/>
                    <count group_id="O3" value="1522"/>
                    <count group_id="O4" value="475"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1449"/>
                    <measurement group_id="O2" value="454"/>
                    <measurement group_id="O3" value="1448"/>
                    <measurement group_id="O4" value="459"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1493"/>
                    <count group_id="O2" value="473"/>
                    <count group_id="O3" value="1492"/>
                    <count group_id="O4" value="474"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1392"/>
                    <measurement group_id="O2" value="440"/>
                    <measurement group_id="O3" value="1392"/>
                    <measurement group_id="O4" value="448"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA, Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1526"/>
                    <count group_id="O2" value="479"/>
                    <count group_id="O3" value="1523"/>
                    <count group_id="O4" value="478"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1498"/>
                    <measurement group_id="O2" value="465"/>
                    <measurement group_id="O3" value="1501"/>
                    <measurement group_id="O4" value="467"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1493"/>
                    <count group_id="O2" value="473"/>
                    <count group_id="O3" value="1492"/>
                    <count group_id="O4" value="474"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1454"/>
                    <measurement group_id="O2" value="456"/>
                    <measurement group_id="O3" value="1448"/>
                    <measurement group_id="O4" value="456"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1526"/>
                    <count group_id="O2" value="479"/>
                    <count group_id="O3" value="1523"/>
                    <count group_id="O4" value="478"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="102"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1411"/>
                    <measurement group_id="O2" value="463"/>
                    <measurement group_id="O3" value="1402"/>
                    <measurement group_id="O4" value="469"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1493"/>
                    <count group_id="O2" value="473"/>
                    <count group_id="O3" value="1492"/>
                    <count group_id="O4" value="474"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="90"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1368"/>
                    <measurement group_id="O2" value="455"/>
                    <measurement group_id="O3" value="1367"/>
                    <measurement group_id="O4" value="458"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN, Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1527"/>
                    <count group_id="O2" value="479"/>
                    <count group_id="O3" value="1523"/>
                    <count group_id="O4" value="478"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1509"/>
                    <measurement group_id="O2" value="471"/>
                    <measurement group_id="O3" value="1500"/>
                    <measurement group_id="O4" value="466"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1493"/>
                    <count group_id="O2" value="473"/>
                    <count group_id="O3" value="1492"/>
                    <count group_id="O4" value="474"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1462"/>
                    <measurement group_id="O2" value="467"/>
                    <measurement group_id="O3" value="1467"/>
                    <measurement group_id="O4" value="469"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1526"/>
                    <count group_id="O2" value="479"/>
                    <count group_id="O3" value="1523"/>
                    <count group_id="O4" value="478"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1457"/>
                    <measurement group_id="O2" value="455"/>
                    <measurement group_id="O3" value="1440"/>
                    <measurement group_id="O4" value="458"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1493"/>
                    <count group_id="O2" value="473"/>
                    <count group_id="O3" value="1492"/>
                    <count group_id="O4" value="474"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Below</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Within</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1406"/>
                    <measurement group_id="O2" value="448"/>
                    <measurement group_id="O3" value="1398"/>
                    <measurement group_id="O4" value="444"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Medically-attended Adverse Events (MAEs)</title>
        <description>MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination. Safety results were tabulated according to age stratification: adults aged 18-64 years and older (&gt;64y).</description>
        <time_frame>Throughout the entire study period (Day 0 - Day 385)</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340274A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2340273A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Medically-attended Adverse Events (MAEs)</title>
          <description>MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination. Safety results were tabulated according to age stratification: adults aged 18-64 years and older (&gt;64y).</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1544"/>
                <count group_id="O2" value="481"/>
                <count group_id="O3" value="1543"/>
                <count group_id="O4" value="480"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="615"/>
                    <measurement group_id="O2" value="247"/>
                    <measurement group_id="O3" value="614"/>
                    <measurement group_id="O4" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)</title>
        <description>Potential immune-mediated diseases (pIMDs) represent a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Safety results were tabulated according to age stratification: adults aged 18-64 years and older (&gt;64y).</description>
        <time_frame>Throughout the entire study period (Day 0 - Day 385)</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340274A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2340273A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)</title>
          <description>Potential immune-mediated diseases (pIMDs) represent a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Safety results were tabulated according to age stratification: adults aged 18-64 years and older (&gt;64y).</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1544"/>
                <count group_id="O2" value="481"/>
                <count group_id="O3" value="1543"/>
                <count group_id="O4" value="480"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Unsolicited Adverse Events (AEs)</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Safety results were tabulated according to age stratification: adults aged 18-64 years and older (&gt;64y).</description>
        <time_frame>Within the 42-day (Days 0-41) post-vaccination period</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340274A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2340273A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Unsolicited Adverse Events (AEs)</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Safety results were tabulated according to age stratification: adults aged 18-64 years and older (&gt;64y).</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1544"/>
                <count group_id="O2" value="481"/>
                <count group_id="O3" value="1543"/>
                <count group_id="O4" value="480"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="495"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="522"/>
                    <measurement group_id="O4" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Safety results were tabulated according to age stratification: adults aged 18-64 years and older (&gt;64y).</description>
        <time_frame>Throughout the entire study period (Day 0 - Day 385)</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2340274A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2340274A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2340273A (18-64 y) Group</title>
            <description>Healthy male or female subjects between and including 18 and 64 years of age, who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2340273A (&gt;64 y) Group</title>
            <description>Healthy male or female subjects older than 64 years of age (&gt;64 y), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Safety results were tabulated according to age stratification: adults aged 18-64 years and older (&gt;64y).</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1544"/>
                <count group_id="O2" value="481"/>
                <count group_id="O3" value="1543"/>
                <count group_id="O4" value="480"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period. Unsolicited AEs: during the 42-day (Days 0-41) post-vaccination period. Serious adverse events (SAE): during the entire study period (Day 0 to Day 385).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GSK2340274A Group</title>
          <description>Healthy male or female subjects between and including 18 to 60 years of age and older (&gt;60 years) and between 18 to 64 years of age and older (&gt;64 years), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E2">
          <title>GSK2340273A Group</title>
          <description>Healthy male or female subjects between and including 18 to 60 years of age and older (&gt;60 years) and between 18 to 64 years of age and older (&gt;64 years), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2025"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="2025"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Splenic vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2025"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Gastric fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Mesenteric vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2025"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2025"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Enterocolitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Histoplasmosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Brain natriuretic peptide increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Electrocardiogram st segment elevation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Enzyme activity decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Bronchioloalveolar carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Follicle centre lymphoma, follicular grade i, ii, iii stage iii</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Glioblastoma multiforme</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Paget's disease of the breast</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Thymoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Small for dates baby</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Urethral perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stevens-johnson syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2025"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2025"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1680" subjects_at_risk="2025"/>
                <counts group_id="E2" subjects_affected="1063" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="183" subjects_affected="181" subjects_at_risk="2025"/>
                <counts group_id="E2" events="116" subjects_affected="116" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="573" subjects_affected="564" subjects_at_risk="2025"/>
                <counts group_id="E2" events="435" subjects_affected="428" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1533" subjects_affected="1530" subjects_at_risk="2025"/>
                <counts group_id="E2" events="509" subjects_affected="508" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="165" subjects_affected="165" subjects_at_risk="2025"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="302" subjects_affected="299" subjects_at_risk="2025"/>
                <counts group_id="E2" events="167" subjects_affected="165" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="709" subjects_affected="698" subjects_at_risk="2025"/>
                <counts group_id="E2" events="329" subjects_affected="326" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="570" subjects_affected="547" subjects_at_risk="2025"/>
                <counts group_id="E2" events="530" subjects_affected="510" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="82" subjects_affected="78" subjects_at_risk="2025"/>
                <counts group_id="E2" events="112" subjects_affected="110" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="124" subjects_affected="122" subjects_at_risk="2025"/>
                <counts group_id="E2" events="131" subjects_affected="126" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="114" subjects_affected="114" subjects_at_risk="2025"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="2023"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="116" subjects_affected="116" subjects_at_risk="2025"/>
                <counts group_id="E2" events="83" subjects_affected="83" subjects_at_risk="2023"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

